In this issue of the Journal, Giordillo et al. assess the determinants of the risk of colorectal neoplasia in patients with ulcerative colitis [UC] from the ENEIDA Spanish cross-sectional cohort.
There is good reason to be perplexed when trying to put together the conflicting data on the chemopreventive effect of thiopurines on the risk of colorectal neoplasia in IBD. As a first illustration, nationwide medico-administrative data from Denmark 3 or UK concluded that there was no effect of thiopurines on the risk of colorectal cancer, whereas data from a Dutch health insurance system showed a magic 90% reduction in the risk of colorectal advanced neoplasia. 5 Among studies from tertiary care centres, there was no protective effect of thiopurines against colorectal cancer in UC reported in studies from Rochester 6 and New York, 7 whereas the most recent study from Chicago suggested a marked protective effect of immunomodulators on the risk of colorectal neoplasia [adjusted OR 0.24; 95% CI:0.08-0.74]. 8 Concept-based critical review of study designs and results may be of some help in making things clearer. It is established that the sequence of molecular events differs notably between sporadic and colitis-associated cancers, but most elementary events are common to both types of cancers. 9 Some molecular anti-carcinogenic effects of 5-amino-salicylates have been suggested. 10 This has never been the case to date for thiopurines. In this context, the chemopreventive effect of thiopurines on colorectal cancer in UC could be mainly due to non-specific anti-inflammatory properties, leading to reduced incidence of inflammation-driven colorectal neoplasia, providing that the 'mean inflammatory burden' of colonic mucosa is lower in patients exposed to thiopurines than in patients not exposed to the drugs.
Starting with this working hypothesis, we first understand why no chemopreventive effect of thiopurines against sporadic colorectal cancer has been demonstrated in patients treated with thiopurines outside the field of IBD, such as transplanted individuals. 11 We should also postulate that the chemopreventive effect of thiopurines in IBD is restricted to patients at risk of inflammation-related colorectal neoplasia. In most of the nationwide studies, patients who were not at excess risk of colitis-associated colorectal cancer [patients with Crohn's disease but without colitis or UC patients with isolated proctitis] have been included. This could have hampered the demonstration of the chemopreventive effect of thiopurines. 3, 4 In the CESAME cohort, which design is much closer to that of a population-based study than that of a tertiary centre study, analysis was stratified according to the existence or not of a longstanding extensive colitis. 12 In patients without longstanding extensive colitis, ie not at excess risk of colitis-associated colorectal cancer, there was no effect of thiopurines, whereas a marked chemopreventive effect [OR 0.28] was shown in patients with longstanding extensive colitis. 12 By definition, virtually all UC patients who are enrolled in a surveillance colonoscopy programme are at increased risk of colitis-associated colorectal cancer. However, no significant protective effect of thiopurines could be evidenced in the first studies restricted to patients undergoing colonoscopy surveillance in tertiary centres. 7, 13 Some of these studies may have been underpowered. 13 In oldest series too, the use of thiopurines was restricted to the most severely ill and inflammatory patients. This was probably the case in the study by Matula et al., in which patients exposed to thiopurines were also more prone to receive corticosteroids, a good marker of uncontrolled inflammatory disease. 7 In the Spanish study, more than 80% of the patients were included in a surveillance colonoscopy programme, and thus at risk of colitis-associated colorectal neoplasia. The design of the study was therefore appropriate for assessing the chemopreventive effect of thiopurines on colorectal neoplasia in UC patients at Journal of Crohn's and Colitis, 2015, 1061-1062 doi:10.1093/ecco-jcc/jjv155
Advance Access publication September 8, 2015 Editorial L. Beaugerie high risk of colitis-associated colitis, like in the CESAME study. The main result tells us that patients ever exposed to thiopurines are at reduced risk of colorectal neoplasia, but the causal relationship advocated in the title of the article is somewhat daring since the analysis was not adjusted for propensity to use drugs and the hypothesis of unmeasured confounders cannot be fully ruled out in observational studies.
Postulating on one side that sustained macroscopic and microscopic inflammation is the main driver of the risk of colitis-associated neoplasia, and on the other side that thiopurines are chemopreventive purely via their anti-inflammatory effects, opens the door for numerous unanswered questions: Have the other anti-inflammatory drugs used in the maintenance treatment of UC [5-amino-salicylates, anti-tumor necrosis factor agents] also a definite chemopreventive action? What is the best mucosal healer 14 in UC? Is the best mucosal healer in UC also the best chemopreventive agent? Should we combine the treatments? Should we initiate the treatments from the diagnosis for the purpose of chemoprevention, aiming to prevent the molecular field changes 15 that arise in colonic mucosa before the detection of neoplasia?
Despite a historical trend towards decreased frequency of colorectal cancer in IBD, possibly attributable to decreased colonic inflammation, the long-term risk of colorectal cancer remains a central element in the long-term prognosis of IBD, particularly in patients with extensive and early-onset colitis. 16 In this context, the question of the chemoprotective effect of long-term IBD treatments is also essential. Much concept-driven tailored clinical research and epidemiology remain to be done in this field, and the current [ENEIDA, CESAME] and imminent [I-CARE] specifically designed observational prospective cohorts progressively emerge as indispensable pieces of the research arsenal, in addition to clinical trials and studies from medico-administrative databases and tertiary care centre cohorts.
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